International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets
Open accessThe DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is one of the most prevalent and life-threatening forms of mental illnesses and a major cause of morbidity worldwide. Currently available antidepressants are effective for most patients, although around 30% are considered treatment resistant (TRD), a condition that is associated with a significant impairment of cognitive function and poor quality of life. In this respect, the identification of the molecular mechanisms contributing to TRD represents an essential step for the design of novel and more efficacious drugs able to modify the clinical course of this disorder and increase remission rates in clinical practice. New insights into the neurobiology of TRD have shed light on the role of a number of different mechanisms, including the glutamatergic system, immune/inflammatory systems, neurotrophin function, and epigenetics. Advances in drug discovery processes in TRD have also influenced the classification of antidepressant drugs and novel classifications are available, such as the neuroscience-based nomenclature that can incorporate such advances in drug development for TRD. This review aims to provide an up-to-date description of key mechanisms in TRD and describe current therapeutic strategies for TRD before examining novel approaches that may ultimately address important neurobiological mechanisms not targeted by currently available antidepressants. All in all, we suggest that drug targeting different neurobiological systems should be able to restore normal function but must also promote resilience to reduce the long-term vulnerability to recurrent depressive episodes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 1×
“…(IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 (IL-12), interferon-g and tumor necrosis factor-a (TNF-a ) (Dowlati et al., 2010; Capuron and Miller, 2011), as well as increased acute phase proteins, chemokines, and cellular adhesion molecules (Maes et al.,…”
BackgroundDanbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Similar findings were found in the large North American multicenter STAR*D (Sequenced Treatment Alternatives to Relieve Depression) study (Trivedi et al., 2006) investigating altogether 2876 outpatients with depression.”
BackgroundResultAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse
McGowan, P. O., Sasaki, A., D'Alessio, A. C., Dymov, S., Labonté, B., Szyf, M., Turecki, G., & Meaney, M. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2270 · Cited by 3,531 · cited 1×
“Indeed, in human brain the promoter of the GR gene is hypermethylated in men abused during childhood (McGowan et al., 2009) and in infants from mothers who self-reported depression during pregnancy (Braithwaite et al., 2015), as well as in a rat model of reduced maternal care (Weaver et al., 2004).”
BackgroundA Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Cuthbert, B. N., & Insel, T. R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-126 · Cited by 3,053
(2013) · The Lancet · doi:10.1016/s0140-6736(12)62129-1 · Cited by 3,010
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“Ketamine rapidly activates synaptic plasticity mediated by glutamatergic receptors, leading to increased number and function of new spine synapses (Li et al., 2010).”
BackgroundCognition and Depression: Current Status and Future Directions
Gotlib, I. H., & Joormann, J. (2010) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.121208.131305 · Cited by 2,420
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 1×
“Indeed, although BDNF is downregulated at cortical and hippocampal level, opposite changes can be found in the mesolimbic system (Berton et al., 2006; Krishnan and Nestler, 2008; Wook Koo et al., 2016), suggesting that effective therapeutic intervention should be able to modulate the neuro-trophin…”
BackgroundNeurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“…(ECT), transcranial magnetic stimulation, deep-brain stimulation, vagal nerve stimulation (Cusin and Dougherty, 2012; Carreno and Frazer, 2017), or even neurosurgical lesion procedures (Patel et al., 2013) have been evaluated in several studies, and they may represent valid therapeutic options.”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Furthermore, blockade of NMDA receptors by ketamine can result in the inhibition of eukaryotic elongation factor 2 (eEF2) kinase, dephosphorylation of eEF2, which may lead to a desuppression of BDNF translation (Autry et al., 2011).”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 2×
“…alterations, including neuronal atrophy, reduced number of spines, and dendritic arborization have been consistently re-ported in the prefrontal cortex and hippocampus of depressed patients (Rajkowska et al., 1999; McEwen and Lasley, 2003; Stockmeier et al., 2004; Duman and Aghajanian, 2012).”
BackgroundRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 2×
“5 mg/l) (Raison et al., 2013).”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 1×
“…its importance, has been challenged by evidence and a number of questions that have brought about a revision of such a “ hypothesis ” that is now framed within more general concepts related to miswir-ing, deficits of neuronal plasticity, and cell-cell communication (Berton and Nestler, 2006).”
BackgroundRajkowska, G., Miguel-Hidalgo, J. J., Wei, J., Dilley, G., Pittman, S. D., Meltzer, H. Y., Overholser, J. C., Roth, B. L., & Stockmeier, C. A. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00041-4 · Cited by 1,477
Epigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400 · cited 3×
“…histone deacetylases (HDACs) levels are significantly increased in peripheral blood cells (Iga et al., 2007; Hobara et al., 2010) and in the nucleus accumbens (Covington et al., 2009) of depressed patients, as well as in mice exposed to chronic stress (Renthal et al., 2007; Covington et al., 2009).”
BackgroundSheline, Y. I., Sanghavi, M., Mintun, M. A., & Gado, M. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05034.1999 · Cited by 1,382 · cited 1×
“Interestingly, an inverse relationship between the total hippocampal volume and the duration of untreated depression has been demonstrated (Sheline et al., 1999).”
BackgroundBrain foods: The effects of nutrients on brain function.
Gómez-Pinilla, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2421 · Cited by 1,372
Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Sen, S., Duman, R., & Sanacora, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.005 · Cited by 1,232
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“The antidepressant efficacy of ketamine in treatment-resistant depression was confirmed by different studies (Ibrahim et al., 2011; Murrough et al., 2013; Papadimitropoulou et al., 2017).”
Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Komatsu, N., Kumakiri, C., Nakazato, M., Watanabe, H., Shinoda, N., Okada, S.-I., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00181-1 · Cited by 1,151 · cited 1×
“Several lines of evidence have shown that the expression of the neurotrophin is reduced in selected brain structures, as well as at the peripheral level, of subjects with depression (Shimizu et al., 2003; Karege et al., 2005; Thompson Ray et al., 2011; Reinhart et al., 2015).”
BackgroundSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141 · cited 1×
“It is worth mentioning that pramipexole, a D3/D2 receptor agonist, is not only the most effective compound in the treatment of depression associated with Parkinson ’ s disease (Seppi et al., 2011), but it has been proposed as an augmentation strategy in TRD (Pae, 2014).”
BackgroundA cholinergic-adrenergic hypothesis of mania and depression
Janowsky, D., Davis, J., El-Yousef, M. K., & Sekerke, H. J. (1972) · The Lancet · doi:10.1016/s0140-6736(72)93021-8 · Cited by 1,134
CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies.
Valkanova, V., Ebmeier, K. P., & Allan, C. L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.06.004 · Cited by 972 · cited 1×
“…recent meta-analyses found the most relevant longitudinal association be-tween two inflammatory markers, namely C-reactive protein and IL-6, and depressive disorders, suggesting that indeed inflammation may contribute to the development of the disease (Valkanova et al., 2013; Smith et al., 2018).”
BackgroundBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“The role of BDNF in the pathophysiology of depression and in the mechanism of action of antidepressant drugs is well known (Altar, 1999; Duman, 2002; Duman and Monteggia, 2006; Bjorkholm and Monteggia, 2016; Calabrese et al., 2016; Cattaneo et al., 2016a).”
BackgroundLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 1×
“…drugs is especially recommended for patients with MDD exhibiting psychotic features, whereas lithium should be preferably considered in patients with MDD displaying high risk for suicidal behavior (Kessing et al., 2005; Cipriani et al., 2013; Bauer et al., 2017; Dold and Kasper, 2017).”
BackgroundHasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846 · cited 1×
“In particular, increased concentrations of glutamate and glutamine have been found in occipital cortex from MDD patients, whereas a decrease of the same neurotransmitters was detected in prefrontal regions (Hasler et al., 2007).”
BackgroundEpigenetic mechanisms and the transgenerational effects of maternal care
Champagne, F. A. (2008) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2008.03.003 · Cited by 812
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808
Hyde, C. L., Nagle, M. W., Tian, C., Chen, X., Paciga, S. A., Wendland, J. R., Tung, J. Y., Hinds, D. A., Perlis, R. H., & Winslow, A. R. (2016) · Nature Genetics · doi:10.1038/ng.3623 · Cited by 784
Cellular changes in the postmortem hippocampus in major depression
Stockmeier, C. A., Mahajan, G. J., Konick, L. C., Overholser, J. C., Jurjus, G. J., Meltzer, H. Y., Uylings, H. B. M., Friedman, L., & Rajkowska, G. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.022 · Cited by 732 · cited 1×
“…alterations, including neuronal atrophy, reduced number of spines, and dendritic arborization have been consistently re-ported in the prefrontal cortex and hippocampus of depressed patients (Rajkowska et al., 1999; McEwen and Lasley, 2003; Stockmeier et al., 2004; Duman and Aghajanian, 2012).”
BackgroundDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659 · cited 2×
“An alternative and innovative approach that is currently proposed for TRD is to selectively target the proinflammatory cytokines primary involved in TRD, such as TNF-a , IL-6, and IL-1 b (Bortolato et al., 2015; Kappelmann et al., 2018).”
BackgroundRaison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630 · cited 1×
“Although it was proposed that such effects may lead to decreased serotonin levels (Remus and Dantzer, 2016), it was demonstrated that the reduction in peripheral blood TRP has no effects on CSF TRP concentrations (Raison et al., 2010).”
BackgroundAntidepressant Actions of Histone Deacetylase Inhibitors
Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., Wu, E. Y., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1758-09.2009 · Cited by 624 · cited 3×
“…histone deacetylases (HDACs) levels are significantly increased in peripheral blood cells (Iga et al., 2007; Hobara et al., 2010) and in the nucleus accumbens (Covington et al., 2009) of depressed patients, as well as in mice exposed to chronic stress (Renthal et al., 2007; Covington et al., 2009).”
BackgroundMajor Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617 · cited 3×
“Interestingly, a positive correlation between the severity of the symptoms of depression and the increase in the inflammatory status has been demonstrated (Maes, 1999; Maes et al., 2016).”
BackgroundKarege, F., Vaudan, G., Schwald, M., Perroud, N., & La Harpe, R. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.12.020 · Cited by 600 · cited 1×
“Several lines of evidence have shown that the expression of the neurotrophin is reduced in selected brain structures, as well as at the peripheral level, of subjects with depression (Shimizu et al., 2003; Karege et al., 2005; Thompson Ray et al., 2011; Reinhart et al., 2015).”
BackgroundHistone Deacetylase 5 Epigenetically Controls Behavioral Adaptations to Chronic Emotional Stimuli
Renthal, W., Maze, I., Krishnan, V., Covington, H. E., Xiao, G., Kumar, A., Russo, S. J., Graham, A., Tsankova, N., Kippin, T. E., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.032 · Cited by 599 · cited 1×
“Although antidepressant combination strategies are frequently used in the pharmacological management of TRD, the evidence for this measure is rather sparse, and meta-analytic findings on this topic were inconclusive (Rocha et al., 2012; Lopes Rocha et al., 2013).”
BackgroundNew Insights in the Biology of BDNF Synthesis and Release: Implications in CNS Function
Greenberg, M. E., Xu, B., Lu, B., & Hempstead, B. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3566-09.2009 · Cited by 597
Inflammation-Induced Anhedonia: Endotoxin Reduces Ventral Striatum Responses to Reward
Eisenberger, N. I., Berkman, E. T., Inagaki, T. K., Rameson, L. T., Mashal, N. M., & Irwin, M. R. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.010 · Cited by 596 · cited 1×
“…to a deficit in dopaminergic mesolimbic pathway combined with a dysfunction in prefrontal glutamatergic system finally leading to the onset of anhedonia, loss of motivation, fatigue, psychomotor re-tardation, and cognitive deficits (Eisenberger et al., 2010; Leggio et al., 2013; Pan et al., 2017).”
BackgroundRole of brain norepinephrine in the behavioral response to stress
Morilak, D. A., Barrera, G., Echevarria, D. J., Garcia, A. S., Hernandez, A., Ma, S., & Petre, C. O. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.007 · Cited by 570
Zhang, J.-C., Yao, W., & Hashimoto, K. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160119094646 · Cited by 538 · cited 1×
“One possible approachmight be to target the BDNF-TrkB signaling pathway (Zhang et al., 2016).”
BackgroundThe histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 17×
“…(Souery et al., 2007; Zaninotto et al., 2013) Psychotic features (Zaninotto et al., 2013) Nonresponse to first antidepressant treatment lifetime (Souery et al., 2007) Personality disorder (DSM-IV criteria) (Souery et al., 2007) Long duration of the current depressive episode (Zaninotto et al.,…”
BackgroundInfluentialSelf-citationInflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
Conradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515
Babenko, O., Kovalchuk, I., & Metz, G. A. S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.013 · Cited by 513 · cited 2×
“Indeed, we know that genetic susceptibility factors may reshape developmental trajectories leading to altered ability to cope or respond to the environment within specific time frames (Babenko et al., 2015).”
BackgroundNational Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry
Mojtabai, R., & Olfson, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.175 · Cited by 479 · cited 2×
“…with different receptor-binding properties (e.g., SSRIs and mirtazapine) have been shown to be the most effective treatment strategies in TRD (Mojtabai and Olfson, 2010; Seemuller et al., 2010; Dold et al., 2016; Thase et al., 2016) and hence can be regarded as evidence-based treatment of…”
BackgroundHypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder
Abdolmaleky, H. M., Cheng, K.-H., Faraone, S. V., Wilcox, M., Glatt, S. J., Gao, F., Smith, C. L., Shafa, R., Aeali, B., Carnevale, J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl253 · Cited by 462
Molendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.98 · Cited by 437 · cited 1×
“…BDNF levels observed in MDD patients (Cattaneo et al., 2010), an effect that correlates with symptomatology improvement (Sen et al., 2008; Cattaneo et al., 2013), suggesting a potential relationship between drug response and the ability to modulate neurotrophic mechanisms (Molendijk et al., 2011).”
BackgroundWalker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421 · cited 1×
“…have been developed over the last 50 – 60 years, the therapeutic response is often partial, and around 20% – 30% of patients are considered treatment resistant or they do not respond adequately to two successive antidepressant treatments under a proper therapeutic regimen (McIntyre et al., 2014).”
BackgroundFurey, M. L., & Drevets, W. C. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1121 · Cited by 417 · cited 2×
“The renewed interest in this field stems from the evidence that the muscarinic M1 and M2 receptor antagonist scopolamine (Witkin et al., 2014) elicits a rapid antidepressant response in patients with MDD (Furey and Drevets, 2006; Drevets and Furey, 2010).”
BackgroundInfluentialInflammation and depression: a causal or coincidental link to the pathophysiology?
Leonard, B. E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.69 · Cited by 409
Early life stress confers lifelong stress susceptibility in mice via ventral tegmental area OTX2
Peña, C. J., Kronman, H. G., Walker, D. M., Cates, H. M., Bagot, R. C., Purushothaman, I., Issler, O., Loh, Y.-H. E., Leong, T., Kiraly, D. D., et al. (2017) · Science · doi:10.1126/science.aan4491 · Cited by 394 · cited 1×
“A further complexity may be due to the fact that such “ etiological ” mechanisms may not necessarily produce a pathologic phenotype, but could represent a predisposing condition to develop MDD if reexposed to challenging precipitating traumatic experiences (Arloth et al., 2015; Pena et al., 2017).”
BackgroundIwata, M., Ota, K. T., Li, X.-Y., Sakaue, F., Li, N., Dutheil, S., Banasr, M., Duric, V., Yamanashi, T., Kaneko, K., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.026 · Cited by 387
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder
Jernigan, C. S., Goswami, D. B., Austin, M. C., Iyo, A. H., Chandran, A., Stockmeier, C. A., & Karolewicz, B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.05.010 · Cited by 386
Pariante, C. M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.001 · Cited by 382
Increased BDNF Promoter Methylation in the Wernicke Area of Suicide Subjects
Keller, S., Sarchiapone, M., Zarrilli, F., Videtič, A., Ferraro, A., Carli, V., Sacchetti, S., Lembo, F., Angiolillo, A., Jovanovic, N., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.9 · Cited by 379 · cited 1×
“Similarly, a hypermethylation of BDNF promoter IV was observed in the Wernicke ’ s area of suicide completers (Keller et al., 2010).”
BackgroundFuchikami, M., Morinobu, S., Segawa, M., Okamoto, Y., Yamawaki, S., Ozaki, N., Inoue, T., Kusumi, I., Koyama, T., Tsuchiyama, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023881 · Cited by 378 · cited 1×
“…reports that HDAC2 and HDAC5 expression is upregulated in leukocytes of patients during the depressive phase but not in remission (Hobara et al., 2010) and that the DNA methylation profile of BDNF (exon I) allows for distinguishing between depressed and control patients (Fuchikami et al., 2011).”
BackgroundTh1, Th2, and Th3 cytokine alterations in major depression
MYINT, A., LEONARD, B., STEINBUSCH, H., & KIM, Y. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.07.008 · Cited by 371 · cited 1×
“Reduced levels of anti-inflammatory cytokines, such as IL-4, IL-10, and TGF-b 1, have been found in the plasma of patients with depression (Maes, 1999; Myint et al., 2005; Musil et al., 2011; Rush et al., 2016) and can significantly contribute to treatment resistance in MDD (Musil et al., 2011).”
BackgroundSynaptic plasticity and mood disorders
Duman, R. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001016 · Cited by 363
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“Buprenorphine is a partial m -opiod receptor agonist and KOR antagonist, which exerts clinically relevant antidepressant effects in TRD patients (Bodkin et al., 1995; Karp et al., 2014).”
BackgroundInflammation, Depression and Dementia: Are they Connected?
Leonard, B. E. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9385-y · Cited by 342 · cited 5×
“Cortisol increases the activity of tryptophan 2,3 dioxygenase (TDO), with an ensuing reduction in available tryptophan and a significant decrease of serotonin levels.”
BackgroundInfluentialWiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61552-9 · Cited by 340 · cited 1×
“Indeed cognitive behavioral therapy has been reported as a valid option in combination with pharmacotherapy for primary care patients with TRD compared with usual care alone (Wiles et al., 2013; Morimoto, 2014).”
BackgroundBrain-derived neurotrophic factor in mood disorders and antidepressant treatments
Castrén, E., & Kojima, M. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.010 · Cited by 337
Poulter, M. O., Du, L., Weaver, I. C. G., Palkovits, M., Faludi, G., Merali, Z., Szyf, M., & Anisman, H. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.028 · Cited by 331 · cited 1×
“Furthermore, the antidepressant action was lasting for 1 week and, different from ketamine, was not associated with psychotomimetic effects (Preskorn et al., 2015).”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Young, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300471 · Cited by 318 · cited 1×
“Moreover, one 6-week pilot study found that 600 mg/day of mifepristone improved depressive symptoms and cognition in patients with treatment-resistant bipolar depression, and this clinically relevant improvement was inversely associated with basal cortisol levels (Young et al., 2004).”
BackgroundBay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304 · cited 2×
“However, activation of indoleamine 2,3dioxygenase and TDO leads to an increased production of the neurotoxins 3-hydroxykynurenine and quinolinic acid, which can contribute to the pathophysiology of MDD by activating the NMDA receptor (Myint and Kim, 2003; Leonard, 2007; Bay-Richter et al., 2015; Remus and Dantzer, 201…”
BackgroundMaternal prenatal depressive symptoms predict infant NR3C1 1F and BDNF IV DNA methylation
Braithwaite, E., Kundakovic, M., Ramchandani, P., Murphy, S., & Champagne, F. (2015) · Epigenetics · doi:10.1080/15592294.2015.1039221 · Cited by 299 · cited 1×
“Indeed, in human brain the promoter of the GR gene is hypermethylated in men abused during childhood (McGowan et al., 2009) and in infants from mothers who self-reported depression during pregnancy (Braithwaite et al., 2015), as well as in a rat model of reduced maternal care (Weaver et al., 2004).”
BackgroundRelapse Following Successful Electroconvulsive Therapy for Major Depression: A Meta-Analysis
Jelovac, A., Kolshus, E., & McLoughlin, D. M. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.149 · Cited by 287
State-dependent changes in hippocampal grey matter in depression
Arnone, D., McKie, S., Elliott, R., Juhasz, G., Thomas, E. J., Downey, D., Williams, S., Deakin, J. F. W., & Anderson, I. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.150 · Cited by 287 · cited 1×
“Moreover gray matter reduction in the hippocampus appears specific to the depressed state and can be considered a potential biomarker for a depressive episode (Arnone et al., 2013).”
BackgroundBurgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Rapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Epigenetic Mechanisms of Depression and Antidepressant Action
Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134540 · Cited by 277 · cited 1×
“The relevance of these mechanisms in TRD is also suggested by the observation that drugs that may be effective in TRD act at epigenetic level (Tsankova et al., 2006; Vialou et al., 2013; Menke and Binder, 2014).”
BackgroundMacQueen, G. M., Yucel, K., Taylor, V. H., Macdonald, K., & Joffe, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.06.027 · Cited by 274 · cited 1×
“On one end, regional brain volumes might be associated with rate and extent of clinical response to antidepressant medication (MacQueen et al., 2008).”
BackgroundDuncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256 · cited 1×
“Indeed, although it has been demonstrated that TRD patients who respond to ketamine show an elevation of serum BDNF (Duncan et al., 2013; Haile et al., 2014), other authors found that the effects of ketamine or ECT in TRD were not associated with changes in blood neuro-trophin levels (Allen et al.,…”
BackgroundHaile, C. N., Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Foulkes, A., Iqbal, S., Mahoney, J. J., De La Garza, R., Charney, D. S., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001119 · Cited by 253
Crossley, N. A., & Bauer, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0617 · Cited by 246
Cattaneo, A., Cattane, N., Begni, V, Pariante, C. M., & Riva, M. A. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.214 · Cited by 244
Self-citationDrevets, W. C., & Furey, M. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.021 · Cited by 241 · cited 3×
“The renewed interest in this field stems from the evidence that the muscarinic M1 and M2 receptor antagonist scopolamine (Witkin et al., 2014) elicits a rapid antidepressant response in patients with MDD (Furey and Drevets, 2006; Drevets and Furey, 2010).”
BackgroundInfluentialFava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232 · cited 4×
“In a randomized, double-blinded, placebo-controlled phase 2 trial, the treatment with 2 mg/2 mg of buprenorphine/samidorphan provided significant anti-depressant effects in MDD with a recent history of nonresponse to SSRIs or SNRIs (Fava et al., 2016b).”
BackgroundMethodInfluentialWook Koo, J., Labonté, B., Engmann, O., Calipari, E. S., Juarez, B., Lorsch, Z., Walsh, J. J., Friedman, A. K., Yorgason, J. T., Han, M.-H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.009 · Cited by 231 · cited 2×
“…at cortical and hippocampal level, opposite changes can be found in the mesolimbic system (Berton et al., 2006; Krishnan and Nestler, 2008; Wook Koo et al., 2016), suggesting that effective therapeutic intervention should be able to modulate the neuro-trophin expression and function with…”
BackgroundMendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Self-citationBelujon, P., & Grace, A. A. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.014 · Cited by 225
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Epigenetic mechanisms of depression
Nestler, E. J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4291 · Cited by 217
Neuroinflammation and Cognitive Aging
Ownby, R. L. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-009-0082-1 · Cited by 212 · cited 1×
“Neuroinflammation is also associated with a reduced response to the treatment with SSRIs (Kulmatycki and Jamali, 2006; Maes et al., 2016), and it may also account for the complex interaction of depression and cognitive deficits in older adults (Ownby, 2010).”
BackgroundGenome-Wide Methylation Changes in the Brains of Suicide Completers
Labonté, B., Suderman, M., Maussion, G., Lopez, J. P., Navarro-Sánchez, L., Yerko, V., Mechawar, N., Szyf, M., Meaney, M. J., & Turecki, G. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12050627 · Cited by 212
Vagal nerve stimulation for treatment-resistant depression
Carreno, F. R., & Frazer, A. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0537-8 · Cited by 208
Iadarola, N. D., Niciu, M. J., Richards, E. M., Vande Voort, J. L., Ballard, E. D., Lundin, N. B., Nugent, A. C., Machado-Vieira, R., & Zarate, C. A. (2015) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315579059 · Cited by 201
Guidotti, G., Calabrese, F., Anacker, C., Racagni, G., Pariante, C. M., & Riva, M. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.225 · Cited by 200
Self-citationRen, J., Li, H., Palaniyappan, L., Liu, H., Wang, J., Li, C., & Rossini, P. M. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.02.004 · Cited by 199 · cited 1×
“…TRD, with a response rate of almost 50% (Heijnen et al., 2010), but it also characterized by a high relapse rate after a successful course of therapy (Jelovac et al., 2013) and by cognitive side effects, which are instead less pronounced with transcranial magnetic stimulation (Ren et al., 2014).”
BackgroundNot fade away: the HPA axis and depression
Cowen, P. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709005558 · Cited by 191 · cited 2×
“Epidemiologic evidence supports a role for stress as a risk factor for depression (Cowen, 2010).”
BackgroundZohar, J., Stahl, S., Moller, H.-J., Blier, P., Kupfer, D., Yamawaki, S., Uchida, H., Spedding, M., Goodwin, G. M., & Nutt, D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.019 · Cited by 186
Altered gene expression of histone deacetylases in mood disorder patients
Hobara, T., Uchida, S., Otsuki, K., Matsubara, T., Funato, H., Matsuo, K., Suetsugi, M., & Watanabe, Y. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.015 · Cited by 185
Metyrapone as Additive Treatment in Major Depression: A Double-blind and Placebo-Controlled Trial
Jahn, H., Schick, M., Kiefer, F., Kellner, M., Yassouridis, A., & Wiedemann, K. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.12.1235 · Cited by 184
Effects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180 · cited 1×
“However Suzuki et al. (2017) recently demonstrated that (2 R ,6 R )-HNK inhibits synaptic NMDARs, triggering the same signaling pathways activated by ketamine (i.e., decreased eEF2 phosphorylation) and proposing that the sustained inhibition of NMDARs by (2 R ,6 R )-HNK can explain the long-lasting…”
BackgroundTadić, A., Müller-Engling, L., Schlicht, K. F., Kotsiari, A., Dreimüller, N., Kleimann, A., Bleich, S., Lieb, K., & Frieling, H. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.58 · Cited by 175
Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines
Bauer, M., Severus, E., Möller, H.-J., Young, A. H., & WFSBP Task Force on Unipolar Depressive Disorders (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2017.1306082 · Cited by 175
mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169 · cited 1×
“Interestingly mGluR2/3 antagonists can target mTOR signaling pathway (Dwyer et al., 2012) and enhance synaptic glutamate levels, leading to enhanced AMPA receptor transmission.”
BackgroundCarvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Epigenetic alterations in depression and antidepressant treatment
Menke, A., & Binder, E. B. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.3/amenke · Cited by 161
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Learned helplessness: unique features and translational value of a cognitive depression model
Vollmayr, B., & Gass, P. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1654-2 · Cited by 155 · cited 1×
“…breed-ings, cLH failed to escape without prior stress exposure (Vollmayr and Henn, 2001), they are anhedonic, and, different from noncongenital LH rats, their helpless behavior is not reversed by antidepressant treatment (Vollmayr et al., 2004; Sartorius et al., 2007; Vollmayr and Gass, 2013).”
BackgroundHaroon, E., & Miller, A. H. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_40 · Cited by 153
Arloth, J., Bogdan, R., Weber, P., Frishman, G., Menke, A., Wagner, K. V., Balsevich, G., Schmidt, M. V., Karbalai, N., Czamara, D., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.05.034 · Cited by 142
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
Allen, A. P., Naughton, M., Dowling, J., Walsh, A., Ismail, F., Shorten, G., Scott, L., McLoughlin, D. M., Cryan, J. F., Dinan, T. G., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.06.033 · Cited by 138
Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., & Santarelli, L. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0838 · Cited by 133
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
George, T. P., Sacco, K. A., Vessicchio, J. C., Weinberger, A. H., & Shytle, R. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b49e · Cited by 128
Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10070 · Cited by 125
Yamawaki, Y., Fuchikami, M., Morinobu, S., Segawa, M., Matsumoto, T., & Yamawaki, S. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.585663 · Cited by 117
Ge, L., Liu, L., Liu, H., Liu, S., Xue, H., Wang, X., Yuan, L., Wang, Z., & Liu, D. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.10.026 · Cited by 106
Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression
Iga, J.-I., Ueno, S.-I., Yamauchi, K., Numata, S., Kinouchi, S., Tayoshi-Shibuya, S., Song, H., & Ohmori, T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.014 · Cited by 105
Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
Sun, Y., Wang, D., Salvadore, G., Hsu, B., Curran, M., Casper, C., Vermeulen, J., Kent, J. M., Singh, J., Drevets, W. C., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.06.014 · Cited by 100 · cited 2×
“Sirukumab is a safe and well-tolerated drug, and improvement in depressive symptoms in patients with rheumatoid arthritis positively correlates with baseline soluble IL-6 receptor levels (Sun et al., 2017).”
BackgroundSomatic therapies for treatment-resistant depression: ECT, TMS, VNS, DBS
Cusin, C., & Dougherty, D. D. (2012) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-2-14 · Cited by 98
Zomkowski, A. D. E., Engel, D., Gabilan, N. H., & Rodrigues, A. L. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.011 · Cited by 94 · cited 1×
“Moreover, the antidepressant-like effects of the SSRI escitalopram are prevented by NMDA receptor activation (Zomkowski et al., 2010).”
BackgroundA New Prediction Model for Evaluating Treatment-Resistant Depression
Kautzky, A., Baldinger-Melich, P., Kranz, G. S., Vanicek, T., Souery, D., Montgomery, S., Mendlewicz, J., Zohar, J., Serretti, A., Lanzenberger, R., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10381 · Cited by 94
Self-citationBschor, T., Kern, H., Henssler, J., & Baethge, C. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16r10749 · Cited by 94
Novel glutamatergic agents for major depressive disorder and bipolar disorder
Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.09.010 · Cited by 92
Papadimitropoulou, K., Vossen, C., Karabis, A., Donatti, C., & Kubitz, N. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277201 · Cited by 91 · cited 1×
“The antidepressant efficacy of ketamine in treatment-resistant depression was confirmed by different studies (Ibrahim et al., 2011; Murrough et al., 2013; Papadimitropoulou et al., 2017).”
Yang, B., Zhang, J.-C., Han, M., Yao, W., Yang, C., Ren, Q., Ma, M., Chen, Q.-X., & Hashimoto, K. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4399-2 · Cited by 91 · cited 1×
“stress-induced alterations of BDNF and synaptic proteins (Yang et al., 2016).”
BackgroundMorimoto, S. S., Wexler, B. E., Liu, J., Hu, W., Seirup, J., & Alexopoulos, G. S. (2014) · Nature Communications · doi:10.1038/ncomms5579 · Cited by 91
BDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13
Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.220 · Cited by 88
Meylan, E. M., Halfon, O., Magistretti, P. J., & Cardinaux, J.-R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.012 · Cited by 87 · cited 2×
“…as vorinostat), a class I and II HDAC inhibitor, partially rescues the molecular alterations and the depressive-like behavior of CRCT1 2 / 2 (CREB-regulated transcription coactivator 1) mice, whereas conventional antidepressants, such as desipramine, do not show any effect (Meylan et al., 2016).”
BackgroundBigio, B., Mathé, A. A., Sousa, V. C., Zelli, D., Svenningsson, P., McEwen, B. S., & Nasca, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603111113 · Cited by 85 · cited 1×
“Accordingly, L-acetylcarnitine, probably influencing the acetylation of H3K27 (Nasca et al., 2013), is able to normalize the phenotype of endogenously depressed Flinders sensitive line rats (Bigio et al., 2016).”
BackgroundRole of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression
Kim, Y.-K., & Na, K.-S. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.03.009 · Cited by 84
Kleimann, A., Kotsiari, A., Sperling, W., Gröschl, M., Heberlein, A., Kahl, K. G., Hillemacher, T., Bleich, S., Kornhuber, J., & Frieling, H. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1336-6 · Cited by 70 · cited 1×
“Accordingly, remitters/responders after ECT treatment showed a significantly lower methylation of exon I at the peripheral level compared with non-remitter/nonresponder subjects (Kleimann et al., 2015).”
BackgroundDold, M., Kautzky, A., Bartova, L., Rabl, U., Souery, D., Mendlewicz, J., Porcelli, S., Serretti, A., Zohar, J., Montgomery, S., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.10.005 · Cited by 66 · cited 11×
“Neverthe-less, adjunctive lithium was less frequently prescribed in pharmacoepidemiologic surveys than augmentation with SGAs (Dold et al., 2016).”
BackgroundMethodInfluentialSelf-citationA Systematic Review of Augmentation Strategies for Patients with Major Depressive Disorder
Fleurence, R., Williamson, R., Jing, Y., Kim, E., Tran, Q.-V., Pikalov, A., & Thase, M. E. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4089 · Cited by 65
Fava, M., Johe, K., Ereshefsky, L., Gertsik, L. G., English, B. A., Bilello, J. A., Thurmond, L. M., Johnstone, J., Dickerson, B. C., Makris, N., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.178 · Cited by 45
Dold, M., Bartova, L., Rupprecht, R., & Kasper, S. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477770 · Cited by 38
Self-citationFrancazio (2015) · doi:10.1016/j.psychres.2015.04.009 · Cited by 35 · cited 1×
“…that TRD patients who respond to ketamine show an elevation of serum BDNF (Duncan et al., 2013; Haile et al., 2014), other authors found that the effects of ketamine or ECT in TRD were not associated with changes in blood neuro-trophin levels (Allen et al., 2015; Rapinesi et al., 2015).”
Pan, Z., Rosenblat, J. D., Swardfager, W., & McIntyre, R. S. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170111144340 · Cited by 34
Colle, R., Cury, C., Chupin, M., Deflesselle, E., Hardy, P., Nasser, G., Falissard, B., Ducreux, D., Colliot, O., & Corruble, E. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.04.009 · Cited by 18
Cited by
Genetic and epigenetic factors associated with depression: an updated overview
Alshaya, D. S. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103311 · Cited by 81
Fornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
López-Solà, C., Subirà, M., Serra-Blasco, M., Vicent-Gil, M., Navarra-Ventura, G., Aguilar, E., Acebillo, S., Palao, D. J., & Cardoner, N. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2020.65 · Cited by 31
“[7], which includes the study performed by the European Group for the Study of Resistant Depression, reported several clinical features significantly associated with treatment resistance.”
BackgroundEpidemiology of treatment resistant depression among major depressive disorder patients in Israel
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04184-8 · Cited by 23
Metadata
- Authors
- Caraci, F., Calabrese, F., Molteni, R., Bartova, L., Dold, M., Leggio, G. M., Fabbri, C., Mendlewicz, J., Racagni, G., Kasper, S., Riva, M. A., & Drago, F.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 70
- Issue
- 3
- Pages
- 475-504
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2805668200
- Cited by
- 73
- References
- 149
- FWCI
- 4.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.